# Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)

> **NCT00000621** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Emphysema
- Lung Diseases
- Lung Diseases, Obstructive
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** all trans retinoic acid
- **DRUG:** 13 cis retinoic acid
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00000621
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** — (—)
- **Last updated:** 2008-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000621, "Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00000621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*